The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
Figure 2
Allograft survival rate of the total number of patients and of those in the responder and nonresponder groups. During followup, the survival rate was 89%, 82%, and 70%, at 6, 12, and 24 months, respectively, in all patients. The responder group showed a significantly higher survival rate compared to the nonresponder group ().
